Gene expression profiling and therapeutic interventions in neurodegenerative diseases: a comprehensive study on potentiality and limits

Bibliography

• Galimberti D, Scarpini E. Progress in Alzheimer's disease. J Neurol 2012;259(2):201-11
   PubMed Web of Science ®Google Scholar
• Heisters D. Parkinson's: symptoms, treatments and research. Br J Nurs 2011;20(9):548-54
   PubMedGoogle Scholar
• Shoulson I, Young AB. Milestones in huntington disease. Mov Disord 2011;26(6):1127-33
   PubMed Web of Science ®Google Scholar
• Benetti F, Legname G. De novo mammalian prion synthesis. Prion 2009;3(4):213-19
   PubMed Web of Science ®Google Scholar
• Yang Y, Adelstein SJ, Kassis AI. Target discovery from data mining approaches. Drug Discov Today 2009;14(3-4):147-54
   PubMed Web of Science ®Google Scholar
• di Bernardo D, Thompson MJ, Gardner TS, Chemogenomic profiling on a genome-wide scale using reverse-engineered gene networks. Nat Biotechnol 2005;23(3):377-83
   PubMed Web of Science ®Google Scholar
• Gardner TS, di Bernardo D, Lorenz D, Inferring genetic networks and identifying compound mode of action via expression profiling. Science 2003;301(5629):102-5
   PubMed Web of Science ®Google Scholar
• Stone JG, Casadesus G, Gustaw-Rothenberg K, Frontiers in Alzheimer's Disease Therapeutics. Ther Adv Chronic Dis 2011;2(1):9-23
   Google Scholar
• Zhang YW, Thompson R, Zhang H, APP processing in Alzheimer's disease. Mol Brain 2011;4:3
   PubMed Web of Science ®Google Scholar
• Bertram L, McQueen MB, Mullin K, Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database. Nat Genet 2007;39(1):17-23
   PubMed Web of Science ®Google Scholar
• Ho L, Guo Y, Spielman L, Altered expression of a-type but not b-type synapsin isoform in the brain of patients at high risk for Alzheimer's disease assessed by DNA microarray technique. Neurosci Lett 2001;298(3):191-4
   PubMed Web of Science ®Google Scholar
• Ho L, Sharma N, Blackman L, From proteomics to biomarker discovery in Alzheimer's disease. Brain Res Brain Res Rev 2005;48(2):360-9
   PubMed Web of Science ®Google Scholar
• Yao PJ, Zhu M, Pyun EI, Defects in expression of genes related to synaptic vesicle trafficking in frontal cortex of Alzheimer's disease. Neurobiol Dis 2003;12(2):97-109
   PubMed Web of Science ®Google Scholar
• Loring JF, Wen X, Lee JM, A gene expression profile of Alzheimer's disease. DNA Cell Biol 2001;20(11):683-95
   PubMed Web of Science ®Google Scholar
• Colangelo V, Schurr J, Ball MJ, Gene expression profiling of 12633 genes in Alzheimer hippocampal CA1: transcription and neurotrophic factor down-regulation and up-regulation of apoptotic and pro-inflammatory signaling. J Neurosci Res 2002;70(3):462-73
   PubMed Web of Science ®Google Scholar
• Murphy MP. Development of lipophilic cations as therapies for disorders due to mitochondrial dysfunction. Expert Opin Biol Ther 2001;1(5):753-64
   PubMed Web of Science ®Google Scholar
• in t' Veld BA, Ruitenberg A, Hofman A, Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease. N Engl J Med 2001;345(21):1515-21
   PubMed Web of Science ®Google Scholar
• Cornelius C, Fastbom J, Winblad B, Aspirin, NSAIDs, risk of dementia, and influence of the apolipoprotein E epsilon 4 allele in an elderly population. Neuroepidemiology 2004;23(3):135-43
   PubMed Web of Science ®Google Scholar
• Lindsay J, Laurin D, Verreault R, Risk factors for Alzheimer's disease: a prospective analysis from the Canadian Study of Health and Aging. Am J Epidemiol 2002;156(5):445-53
   PubMed Web of Science ®Google Scholar
• Liu G, Men P, Kudo W, Nanoparticle-chelator conjugates as inhibitors of amyloid-beta aggregation and neurotoxicity: a novel therapeutic approach for Alzheimer disease. Neurosci Lett 2009;455(3):187-90
   PubMed Web of Science ®Google Scholar
• Liang WS, Dunckley T, Beach TG, Altered neuronal gene expression in brain regions differentially affected by Alzheimer's disease: a reference data set. Physiol Genomics 2008;33(2):240-56
   PubMed Web of Science ®Google Scholar
• Sullivan PF, Fan C, Perou CM. Evaluating the comparability of gene expression in blood and brain. Am J Med Genet B Neuropsychiatr Genet 2006;141B(3):261-8
   PubMed Web of Science ®Google Scholar
• Booij BB, Lindahl T, Wetterberg P, A gene expression pattern in blood for the early detection of Alzheimer's disease. J Alzheimers Dis 2011;23(1):109-19
   PubMed Web of Science ®Google Scholar
• Nguyen DV, Rocke DM. Tumor classification by partial least squares using microarray gene expression data. Bioinformatics 2002;18(1):39-50
   PubMed Web of Science ®Google Scholar
• Gidskehaug L, Anderssen E, Flatberg A, A framework for significance analysis of gene expression data using dimension reduction methods. BMC Bioinformatics 2007;8:346
   PubMedGoogle Scholar
• Scherzer CR, Offe K, Gearing M, Loss of apolipoprotein E receptor LR11 in Alzheimer disease. Arch Neurol 2004;61(8):1200-5
   PubMed Web of Science ®Google Scholar
• Dodson SE, Gearing M, Lippa CF, LR11/SorLA expression is reduced in sporadic Alzheimer disease but not in familial Alzheimer disease. J Neuropathol Exp Neurol 2006;65(9):866-72
   PubMed Web of Science ®Google Scholar
• Sager KL, Wuu J, Leurgans SE, Neuronal LR11/sorLA expression is reduced in mild cognitive impairment. Ann Neurol 2007;62(6):640-7
   PubMed Web of Science ®Google Scholar
• Rogaeva E, Meng Y, Lee JH, The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease. Nat Genet 2007;39(2):168-77
   PubMed Web of Science ®Google Scholar
• Reitz C, Cheng R, Rogaeva E, Meta-analysis of the association between variants in SORL1 and Alzheimer disease. Arch Neurol 2011;68(1):99-106
   PubMed Web of Science ®Google Scholar
• Chen KD, Chang PT, Ping YH, Gene expression profiling of peripheral blood leukocytes identifies and validates ABCB1 as a novel biomarker for Alzheimer's disease. Neurobiol Dis 2011;43(3):698-705
   PubMed Web of Science ®Google Scholar
• Forero DA. Genome-wide expression profiles in Alzheimer's and Parkinson's diseases. In preparation (http://sites.google.com/site/compgensite/ad-pd-array-list)
   Google Scholar
• Brookmeyer R, Johnson E, Ziegler-Graham K, Forecasting the global burden of Alzheimer's disease. Alzheimers Dement 2007;3(3):186-91
   PubMed Web of Science ®Google Scholar
• Corrada MM, Kawas CH, Hallfrisch J, Reduced risk of Alzheimer's disease with high folate intake: the Baltimore Longitudinal Study of Aging. Alzheimers Dement 2005;1(1):11-18
   PubMedGoogle Scholar
• Zandi PP, Anthony JC, Khachaturian AS, Reduced risk of Alzheimer disease in users of antioxidant vitamin supplements: the Cache County Study. Arch Neurol 2004;61(1):82-8
   PubMed Web of Science ®Google Scholar
• Sano M, Ernesto C, Thomas RG, A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's disease cooperative study. N Engl J Med 1997;336(17):1216-22
   PubMed Web of Science ®Google Scholar
• Aisen PS, Davis KL, Berg JD, A randomized controlled trial of prednisone in Alzheimer's disease. Alzheimer's disease cooperative study. Neurology 2000;54(3):588-93
   PubMed Web of Science ®Google Scholar
• Aisen PS, Schafer KA, Grundman M, Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. JAMA 2003;289(21):2819-26
   PubMed Web of Science ®Google Scholar
• Van Gool WA, Weinstein HC, Scheltens P, Effect of hydroxychloroquine on progression of dementia in early Alzheimer's disease: an 18-month randomised, double-blind, placebo-controlled study. Lancet 2001;358(9280):455-60
   PubMed Web of Science ®Google Scholar
• Reines SA, Block GA, Morris JC, Rofecoxib: no effect on Alzheimer's disease in a 1-year, randomized, blinded, controlled study. Neurology 2004;62(1):66-71
   PubMed Web of Science ®Google Scholar
• Strozyk D, Bush AI. The role of metal ions in neurology. An introduction. Met Ions Life Sci 2006;1:1-7
   Google Scholar
• Parks JK, Smith TS, Trimmer PA, Neurotoxic abeta peptides increase oxidative stress in vivo through NMDA-receptor and nitric-oxide-synthase mechanisms, and inhibit complex IV activity and induce a mitochondrial permeability transition in vitro. J Neurochem 2001;76(4):1050-6
   PubMed Web of Science ®Google Scholar
• Doody RS, Gavrilova SI, Sano M, Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study. Lancet 2008;372(9634):207-15
   PubMed Web of Science ®Google Scholar
• Bowen RL, Isley JP, Atkinson RL. An association of elevated serum gonadotropin concentrations and Alzheimer disease? J Neuroendocrinol 2000;12(4):351-4
   PubMed Web of Science ®Google Scholar
• Short RA, Bowen RL, O'Brien PC, Elevated gonadotropin levels in patients with Alzheimer disease. Mayo Clin Proc 2001;76(9):906-9
   PubMed Web of Science ®Google Scholar
• Webber KM, Casadesus G, Bowen RL, Evidence for the role of luteinizing hormone in Alzheimer disease. Endocr Metab Immune Disord Drug Targets 2007;7(4):300-3
   PubMedGoogle Scholar
• Noble W, Planel E, Zehr C, Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo. Proc Natl Acad Sci USA 2005;102(19):6990-5
   PubMed Web of Science ®Google Scholar
• Neugroschl J, Sano M. An update on treatment and prevention strategies for Alzheimer's disease. Curr Neurol Neurosci Rep 2009;9(5):368-76
   PubMed Web of Science ®Google Scholar
• Luo W, Dou F, Rodina A, Roles of heat-shock protein 90 in maintaining and facilitating the neurodegenerative phenotype in tauopathies. Proc Natl Acad Sci USA 2007;104(22):9511-16
   PubMed Web of Science ®Google Scholar
• Himeno E, Ohyagi Y, Ma L, Apomorphine treatment in Alzheimer mice promoting amyloid-beta degradation. Ann Neurol 2011;69(2):248-56
   PubMed Web of Science ®Google Scholar
• Olcese JM, Cao C, Mori T, Protection against cognitive deficits and markers of neurodegeneration by long-term oral administration of melatonin in a transgenic model of Alzheimer disease. J Pineal Res 2009;47(1):82-96
   PubMed Web of Science ®Google Scholar
• Shah S, Federoff HJ. Therapeutic potential of vaccines for Alzheimer's disease. Immunotherapy 2011;3(2):287-98
   PubMed Web of Science ®Google Scholar
• Menendez-Gonzalez M, Perez-Pinera P, Martinez-Rivera M, Immunotherapy for Alzheimer's disease: rational basis in ongoing clinical trials. Curr Pharm Des 2011;17(5):508-20
   PubMed Web of Science ®Google Scholar
• Handley OJ, Naji JJ, Dunnett SB, Pharmaceutical, cellular and genetic therapies for Huntington's disease. Clin Sci (Lond) 2006;110(1):73-88
   PubMed Web of Science ®Google Scholar
• Vonsattel JP, Myers RH, Stevens TJ, Neuropathological classification of Huntington's disease. J Neuropathol Exp Neurol 1985;44(6):559-77
   PubMed Web of Science ®Google Scholar
• Hedreen JC, Peyser CE, Folstein SE, Neuronal loss in layers V and VI of cerebral cortex in Huntington's disease. Neurosci Lett 1991;133(2):257-61
   PubMed Web of Science ®Google Scholar
• Jarabek BR, Yasuda RP, Wolfe BB. Regulation of proteins affecting NMDA receptor-induced excitotoxicity in a Huntington's mouse model. Brain 2004;127(Pt 3):505-16
   PubMedGoogle Scholar
• Li JY, Plomann M, Brundin P. Huntington's disease: a synaptopathy? Trends Mol Med 2003;9(10):414-20
   PubMed Web of Science ®Google Scholar
• Beal MF, Ferrante RJ. Experimental therapeutics in transgenic mouse models of Huntington's disease. Nat Rev Neurosci 2004;5(5):373-84
   PubMed Web of Science ®Google Scholar
• Kumar P, Kalonia H, Kumar A. Huntington's disease: pathogenesis to animal models. Pharmacol Rep 2010;62(1):1-14
   PubMed Web of Science ®Google Scholar
• Cha JH. Transcriptional signatures in Huntington's disease. Prog Neurobiol 2007;83(4):228-48
   PubMed Web of Science ®Google Scholar
• Hodges A, Strand AD, Aragaki AK, Regional and cellular gene expression changes in human Huntington's disease brain. Hum Mol Genet 2006;15(6):965-77
   PubMed Web of Science ®Google Scholar
• Hannan AJ. Novel therapeutic targets for Huntington's disease. Expert Opin Ther Targets 2005;9(4):639-50
   PubMed Web of Science ®Google Scholar
• Krobitsch S, Kazantsev AG. Huntington's disease: from molecular basis to therapeutic advances. Int J Biochem Cell Biol 2011;43(1):20-4
   PubMed Web of Science ®Google Scholar
• Hersch SM, Rosas HD. Neuroprotection for Huntington's disease: ready, set, slow. Neurotherapeutics 2008;5(2):226-36
   PubMed Web of Science ®Google Scholar
• Yamamoto A, Lucas JJ, Hen R. Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease. Cell 2000;101(1):57-66
   PubMed Web of Science ®Google Scholar
• Diaz-Hernandez M, Torres-Peraza J, Salvatori-Abarca A, Full motor recovery despite striatal neuron loss and formation of irreversible amyloid-like inclusions in a conditional mouse model of Huntington's disease. J Neurosci 2005;25(42):9773-81
   PubMed Web of Science ®Google Scholar
• Heiser V, Engemann S, Brocker W, Identification of benzothiazoles as potential polyglutamine aggregation inhibitors of Huntington's disease by using an automated filter retardation assay. Proc Natl Acad Sci USA 2002;99(Suppl 4):16400-6
   PubMedGoogle Scholar
• Morgan JC, Mehta SH, Sethi KD. Biomarkers in Parkinson's disease. Curr Neurol Neurosci Rep 2010;10(6):423-30
   PubMed Web of Science ®Google Scholar
• de Lau LM, Breteler MM. Epidemiology of Parkinson's disease. Lancet Neurol 2006;5(6):525-35
   PubMed Web of Science ®Google Scholar
• Greggio E, Bisaglia M, Civiero L, Leucine-rich repeat kinase 2 and alpha-synuclein: intersecting pathways in the pathogenesis of Parkinson's disease? Mol Neurodegener 2011;6(1):6
   PubMedGoogle Scholar
• Warner TT, Schapira AH. Genetic and environmental factors in the cause of Parkinson's disease. Ann Neurol 2003;53(Suppl 3):S16-23; discussion S-5
   PubMed Web of Science ®Google Scholar
• Gibb WR, Lees AJ. The significance of the Lewy body in the diagnosis of idiopathic Parkinson's disease. Neuropathol Appl Neurobiol 1989;15(1):27-44
   PubMed Web of Science ®Google Scholar
• Sundal C, Fujioka S, Uitti RJ, Autosomal dominant Parkinson's disease. Parkinsonism Relat Disord 2012;18(Suppl 1):S7-10
   PubMedGoogle Scholar
• Polymeropoulos MH, Lavedan C, Leroy E, Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 1997;276(5321):2045-7
   PubMed Web of Science ®Google Scholar
• Kitada T, Asakawa S, Hattori N, Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 1998;392(6676):605-8
   PubMed Web of Science ®Google Scholar
• Bonifati V, Rizzu P, van Baren MJ, Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science 2003;299(5604):256-9
   PubMed Web of Science ®Google Scholar
• Valente EM, Abou-Sleiman PM, Caputo V, Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science 2004;304(5674):1158-60
   PubMed Web of Science ®Google Scholar
• Singleton AB, Farrer M, Johnson J, alpha-Synuclein locus triplication causes Parkinson's disease. Science 2003;302(5646):841
   PubMed Web of Science ®Google Scholar
• Leroy E, Boyer R, Auburger G, The ubiquitin pathway in Parkinson's disease. Nature 1998;395(6701):451-2
   PubMed Web of Science ®Google Scholar
• Nalls MA, Plagnol V, Hernandez DG, Imputation of sequence variants for identification of genetic risks for Parkinson's disease: a meta-analysis of genome-wide association studies. Lancet 2011;377(9766):641-9
   PubMed Web of Science ®Google Scholar
• El-Agnaf OM, Salem SA, Paleologou KE, Detection of oligomeric forms of alpha-synuclein protein in human plasma as a potential biomarker for Parkinson's disease. FASEB J 2006;20(3):419-25
   PubMed Web of Science ®Google Scholar
• Mollenhauer B, Cullen V, Kahn I, Direct quantification of CSF alpha-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration. Exp Neurol 2008;213(2):315-25
   PubMed Web of Science ®Google Scholar
• Hoepken HH, Gispert S, Azizov M, Parkinson patient fibroblasts show increased alpha-synuclein expression. Exp Neurol 2008;212(2):307-13
   PubMed Web of Science ®Google Scholar
• Ihara Y, Chuda M, Kuroda S, Hydroxyl radical and superoxide dismutase in blood of patients with Parkinson's disease: relationship to clinical data. J Neurol Sci 1999;170(2):90-5
   PubMed Web of Science ®Google Scholar
• Sato S, Mizuno Y, Hattori N. Urinary 8-hydroxydeoxyguanosine levels as a biomarker for progression of Parkinson disease. Neurology 2005;64(6):1081-3
   PubMed Web of Science ®Google Scholar
• Schwarzschild MA, Schwid SR, Marek K, Serum urate as a predictor of clinical and radiographic progression in Parkinson disease. Arch Neurol 2008;65(6):716-23
   PubMed Web of Science ®Google Scholar
• Schlesinger I, Schlesinger N. Uric acid in Parkinson's disease. Mov Disord 2008;23(12):1653-7
   PubMed Web of Science ®Google Scholar
• Ascherio A, LeWitt PA, Xu K, Urate as a predictor of the rate of clinical decline in Parkinson disease. Arch Neurol 2009;66(12):1460-8
   PubMed Web of Science ®Google Scholar
• Hauser MA, Li YJ, Xu H, Expression profiling of substantia nigra in Parkinson disease, progressive supranuclear palsy, and frontotemporal dementia with parkinsonism. Arch Neurol 2005;62(6):917-21
   PubMed Web of Science ®Google Scholar
• Mandel S, Grunblatt E, Riederer P, Gene expression profiling of sporadic Parkinson's disease substantia nigra pars compacta reveals impairment of ubiquitin-proteasome subunits, SKP1A, aldehyde dehydrogenase, and chaperone HSC-70. Ann N Y Acad Sci 2005;1053:356-75
   PubMed Web of Science ®Google Scholar
• Duke DC, Moran LB, Kalaitzakis ME, Transcriptome analysis reveals link between proteasomal and mitochondrial pathways in Parkinson's disease. Neurogenetics 2006;7(3):139-48
   PubMed Web of Science ®Google Scholar
• Moran LB, Duke DC, Deprez M, Whole genome expression profiling of the medial and lateral substantia nigra in Parkinson's disease. Neurogenetics 2006;7(1):1-11
   PubMed Web of Science ®Google Scholar
• Hastie T, Tibshirani R, Eisen MB, 'Gene shaving' as a method for identifying distinct sets of genes with similar expression patterns. Genome Biol 2000;1(2):RESEARCH0003
   PubMedGoogle Scholar
• McRitchie DA, Hardman CD, Halliday GM. Cytoarchitectural distribution of calcium binding proteins in midbrain dopaminergic regions of rats and humans. J Comp Neurol 1996;364(1):121-50
   PubMed Web of Science ®Google Scholar
• Grimm J, Mueller A, Hefti F, Molecular basis for catecholaminergic neuron diversity. Proc Natl Acad Sci USA 2004;101(38):13891-6
   PubMed Web of Science ®Google Scholar
• Greene JG, Dingledine R, Greenamyre JT. Gene expression profiling of rat midbrain dopamine neurons: implications for selective vulnerability in parkinsonism. Neurobiol Dis 2005;18(1):19-31
   PubMed Web of Science ®Google Scholar
• Matus A. MARCKS for maintenance in dendritic spines. Neuron 2005;48(1):4-5
   PubMed Web of Science ®Google Scholar
• Paradis E, Clement S, Julien P, Lipoprotein lipase affects the survival and differentiation of neural cells exposed to very low density lipoprotein. J Biol Chem 2003;278(11):9698-705
   PubMed Web of Science ®Google Scholar
• Chung CY, Seo H, Sonntag KC, Cell type-specific gene expression of midbrain dopaminergic neurons reveals molecules involved in their vulnerability and protection. Hum Mol Genet 2005;14(13):1709-25
   PubMed Web of Science ®Google Scholar
• Inaba S, Li C, Shi YE, Synuclein gamma inhibits the mitotic checkpoint function and promotes chromosomal instability of breast cancer cells. Breast Cancer Res Treat 2005;94(1):25-35
   PubMed Web of Science ®Google Scholar
• Kress GJ, Reynolds IJ. Dopaminergic neurotoxins require excitotoxic stimulation in organotypic cultures. Neurobiol Dis 2005;20(3):639-45
   PubMed Web of Science ®Google Scholar
• Greenamyre JT, Sherer TB, Betarbet R, Complex I and Parkinson's disease. IUBMB Life 2001;52(3-5):135-41
   PubMed Web of Science ®Google Scholar
• Betarbet R, Sherer TB, MacKenzie G, Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat Neurosci 2000;3(12):1301-6
   PubMed Web of Science ®Google Scholar
• Palacino JJ, Sagi D, Goldberg MS, Mitochondrial dysfunction and oxidative damage in parkin-deficient mice. J Biol Chem 2004;279(18):18614-22
   PubMed Web of Science ®Google Scholar
• Biagioli M, Pinto M, Cesselli D, Unexpected expression of alpha- and beta-globin in mesencephalic dopaminergic neurons and glial cells. Proc Natl Acad Sci USA 2009;106(36):15454-9
   PubMed Web of Science ®Google Scholar
• Scherzer CR, Eklund AC, Morse LJ, Molecular markers of early Parkinson's disease based on gene expression in blood. Proc Natl Acad Sci USA 2007;104(3):955-60
   PubMed Web of Science ®Google Scholar
• Mutez E, Larvor L, Lepretre F, Transcriptional profile of Parkinson blood mononuclear cells with LRRK2 mutation. Neurobiol Aging 2010;32(10):1839-48
   PubMed Web of Science ®Google Scholar
• Zheng B, Liao Z, Locascio JJ, PGC-1alpha, a potential therapeutic target for early intervention in Parkinson's disease. Sci Transl Med 2010;2(52):52ra73
   PubMed Web of Science ®Google Scholar
• Taccioli C, Tegner J, Maselli V, ParkDB: a Parkinson's disease gene expression database. Database (Oxford) 2011;2011:bar007
   PubMedGoogle Scholar
• Rezak M. Current pharmacotherapeutic treatment options in Parkinson's disease. Dis Mon 2007;53(4):214-22
   PubMedGoogle Scholar
• Cotzias GC, Van Woert MH, Schiffer LM. Aromatic amino acids and modification of parkinsonism. N Engl J Med 1967;276(7):374-9
   PubMed Web of Science ®Google Scholar
• Chen JJ, Wilkinson JR. The Monoamine Oxidase Type B Inhibitor Rasagiline in the Treatment of Parkinson Disease: Is Tyramine a Challenge? J Clin Pharmacol 2011. [Epub ahead of print]
   Google Scholar
• Weinreb O, Amit T, Bar-Am O, Rasagiline: a novel anti-Parkinsonian monoamine oxidase-B inhibitor with neuroprotective activity. Prog Neurobiol 2010;92(3):330-44
   PubMed Web of Science ®Google Scholar
• Prusiner SB. Prions. Proc Natl Acad Sci USA 1998;95(23):13363-83
   PubMed Web of Science ®Google Scholar
• Mead S, Stumpf MP, Whitfield J, Balancing selection at the prion protein gene consistent with prehistoric kurulike epidemics. Science 2003;300(5619):640-3
   PubMed Web of Science ®Google Scholar
• Collinge J, Clarke AR. A general model of prion strains and their pathogenicity. Science 2007;318(5852):930-6
   PubMed Web of Science ®Google Scholar
• Legname G, Nguyen HO, Peretz D, Continuum of prion protein structures enciphers a multitude of prion isolate-specified phenotypes. Proc Natl Acad Sci USA 2006;103(50):19105-10
   PubMed Web of Science ®Google Scholar
• Aguzzi A, Sigurdson C, Heikenwaelder M. Molecular mechanisms of prion pathogenesis. Annu Rev Pathol 2008;3:11-40
   PubMed Web of Science ®Google Scholar
• van der Kamp MW, Daggett V. The consequences of pathogenic mutations to the human prion protein. Protein Eng Des Sel 2009;22(8):461-8
   PubMed Web of Science ®Google Scholar
• Benetti F, Gasperini L, Zampieri M, Gene expression profiling to identify druggable targets in prion diseases. Expert Opin Drug Discov 2010;5(2):177-202
   PubMed Web of Science ®Google Scholar
• Xiang W, Windl O, Westner IM, Cerebral gene expression profiles in sporadic Creutzfeldt-Jakob disease. Ann Neurol 2005;58(2):242-57
   PubMed Web of Science ®Google Scholar
• Trevitt CR, Collinge J. A systematic review of prion therapeutics in experimental models. Brain 2006;129(Pt 9):2241-65
   PubMed Web of Science ®Google Scholar
• Masullo C, Macchi G, Xi YG, Failure to ameliorate Creutzfeldt-Jakob disease with amphotericin B therapy. J Infect Dis 1992;165(4):784-5
   PubMed Web of Science ®Google Scholar
• Stewart LA, Rydzewska LH, Keogh GF, Systematic review of therapeutic interventions in human prion disease. Neurology 2008;70(15):1272-81
   PubMed Web of Science ®Google Scholar
• Pocchiari M, Casaccia P, Ladogana A. Amphotericin B: a novel class of antiscrapie drugs. J Infect Dis 1989;160(5):795-802
   PubMed Web of Science ®Google Scholar
• Brajtburg J, Elberg S, Bolard J, Interaction of plasma proteins and lipoproteins with amphotericin B. J Infect Dis 1984;149(6):986-97
   PubMed Web of Science ®Google Scholar
• Taraboulos A, Scott M, Semenov A, Cholesterol depletion and modification of COOH-terminal targeting sequence of the prion protein inhibit formation of the scrapie isoform. J Cell Biol 1995;129(1):121-32
   PubMed Web of Science ®Google Scholar
• Bate C, Salmona M, Diomede L, Squalestatin cures prion-infected neurons and protects against prion neurotoxicity. J Biol Chem 2004;279(15):14983-90
   PubMed Web of Science ®Google Scholar
• Mok SW, Thelen KM, Riemer C, Simvastatin prolongs survival times in prion infections of the central nervous system. Biochem Biophys Res Commun 2006;348(2):697-702
   PubMed Web of Science ®Google Scholar
• Kempster S, Bate C, Williams A. Simvastatin treatment prolongs the survival of scrapie-infected mice. Neuroreport 2007;18(5):479-82
   PubMed Web of Science ®Google Scholar
• Engelstein R, Grigoriadis N, Greig NH, Inhibition of P53-related apoptosis had no effect on PrP(Sc) accumulation and prion disease incubation time. Neurobiol Dis 2005;18(2):282-5
   PubMed Web of Science ®Google Scholar
• Perovic S, Schroder HC, Pergande G, Effect of flupirtine on Bcl-2 and glutathione level in neuronal cells treated in vitro with the prion protein fragment (PrP106-126). Exp Neurol 1997;147(2):518-24
   PubMed Web of Science ®Google Scholar
• Sigurdsson EM, Brown DR, Alim MA, Copper chelation delays the onset of prion disease. J Biol Chem 2003;278(47):46199-202
   PubMed Web of Science ®Google Scholar
• Drisko JA. The use of antioxidants in transmissible spongiform encephalopathies: a case report. J Am Coll Nutr 2002;21(1):22-5
   PubMed Web of Science ®Google Scholar
• Chevyreva I, Faull RL, Green CR, Assessing RNA quality in postmortem human brain tissue. Exp Mol Pathol 2008;84(1):71-7
   PubMed Web of Science ®Google Scholar
• Lipska BK, Deep-Soboslay A, Weickert CS, Critical factors in gene expression in postmortem human brain: focus on studies in schizophrenia. Biol Psychiatry 2006;60(6):650-8
   PubMed Web of Science ®Google Scholar
• Sutherland GT, Janitz M, Kril JJ. Understanding the pathogenesis of Alzheimer's disease: will RNA-Seq realize the promise of transcriptomics? J Neurochem 2011;116(6):937-46
   PubMed Web of Science ®Google Scholar
• Wang Z, Gerstein M, Snyder M. RNA-Seq: a revolutionary tool for transcriptomics. Nat Rev Genet 2009;10(1):57-63
   PubMed Web of Science ®Google Scholar
• Martin JA, Wang Z. Next-generation transcriptome assembly. Nat Rev Genet 2011;12(10):671-82
   PubMed Web of Science ®Google Scholar
• Twine NA, Janitz K, Wilkins MR, Whole transcriptome sequencing reveals gene expression and splicing differences in brain regions affected by Alzheimer's disease. PLoS ONE 2011;6(1):e16266
   PubMedGoogle Scholar
• Leskovjan AC, Lanzirotti A, Miller LM. Amyloid plaques in PSAPP mice bind less metal than plaques in human Alzheimer's disease. Neuroimage 2009;47(4):1215-20
   PubMed Web of Science ®Google Scholar
• Pushie MJ, Pickering IJ, Martin GR, Prion protein expression level alters regional copper, iron and zinc content in the mouse brain. Metallomics 2011;3(2):206-14
   PubMed Web of Science ®Google Scholar
• Domazet B, Maclennan GT, Lopez-Beltran A, Laser capture microdissection in the genomic and proteomic era: targeting the genetic basis of cancer. Int J Clin Exp Pathol 2008;1(6):475-88
   PubMed Web of Science ®Google Scholar